SFMN
Société Française de Médecine Nucléaire

SFMN
Société Française de Médecine Nucléaire
et Imagerie Moléculaire

SFMN
Société Française de Médecine Nucléaire
et Imagerie Moléculaire

SFMN
Société Française de Médecine Nucléaire
et Imagerie Moléculaire

Le traitement par Zévalin® yttrium 90 - VIII. REFERENCES

VIII. REFERENCES

 

  1. Gordon LI et coll. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004 103:4429-31.
  2. Zhu X. Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004 1:20-3.
  3. Zimmer AM. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004 1:14-9.
  4. Borghaei H et coll. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004 1:4-9.
  5. Conti PS. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. Semin Nucl Med. 2004 1:2-3.
  6. Wiseman GA et coll. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000 Jul;27(7):766-77.
  7. Wiseman GA et coll Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94
  8. Wiseman GA et coll. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003 Mar;44(3):465-74.

 

 

 

Designed by SFMN - ACORAMEN